Loading organizations...
Grey Sky Venture Partners is an early-stage venture capital firm specializing in life sciences and healthcare innovation, with offices in Menlo Park, California, and Bellevue, Washington. The firm provides capital and intellectual property support to entrepreneurs developing diagnostic and therapeutic solutions, primarily in the healthcare and medical technology sectors. Investment sizes typically range from $1-5 million, with documented seed and early-stage funding rounds. They actively work with portfolio companies on strategic planning and team building, including a Series C investment in Inflammatix. The firm's last documented investment was in Inflammatix on January 10, 2020, and as of 2020, it was classified as "not-active" based on investment activity. Grey Sky Venture Partners was founded in 2016 by Michael, Paul, and Todd.
Grey Sky Venture Partners has 5 tracked investments across 4 companies. The latest tracked deal is $7.7M Other Equity / Series A in Casca in November 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 25, 2019 | Casca | $7.7M Other Equity / Series A | Tobias Lütke, Hikma Ventures, Khosla Ventures | First Star Ventures, Pacific Health Ventures |
| Oct 3, 2019 | AmacaThera | $3.6M Seed | Viva Ventures Biotech Group | Peter VAN DER Velden, Mba, M.sc. |
| Jan 1, 2019 | Modulim | $7.0M Series B | Pangaea Ventures | Fouse, AL Wiegman, Mitsubishi UFJ Capital |
| Nov 16, 2017 | Modulim | $4.1M Grant / Series A | Grey SKY Venture Partners | Fresenius Medical Care Ventures, Mitsuharu Miwa, Mitsubishi UFJ Capital, National Institute OF Arthritis And Musculoskeletal And Skin Diseases |
| Apr 24, 2017 | Sonavex, Inc. | $3.0M Grant / Series A | Grey SKY Venture Partners | Abell Foundation, CRCM Ventures, National Science Foundation, TEDCO |
